A Randomized, Open-label, Single-center, Phase II Trial to Explore the Safety and Efficacy of GC1102 and Determine Its Optimal Dose After Intravenous Administration in HBV-related Liver Transplant Recipients
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2016
At a glance
- Drugs GC 1102 (Primary)
- Indications Hepatitis B
- Focus Proof of concept; Therapeutic Use
- Sponsors Green Cross
- 29 Jun 2016 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.